{"id":6117,"date":"2015-07-01T14:12:29","date_gmt":"2015-07-01T14:12:29","guid":{"rendered":"\/?p=6117"},"modified":"2015-07-01T14:39:46","modified_gmt":"2015-07-01T14:39:46","slug":"pharmacyte-biotech-inc-otcmktspmcb-pops-on-new-pr","status":"publish","type":"post","link":"\/articles\/pharmacyte-biotech-inc-otcmktspmcb-pops-on-new-pr\/","title":{"rendered":"Pharmacyte Biotech Inc (OTCMKTS:PMCB) Pops on New PR"},"content":{"rendered":"\n

On Friday Pharmacyte Biotech Inc (OTCMKTS:PMCB<\/a>) was back to lows of just over $0.10 per share. A press release that the company dropped near the opening bell yesterday reversed its red streak and pushed PMCB<\/a> to a close 22% in the green.<\/p>\n

The company announced it will be featured on the Discovery Channel, in a morning news magazine segment called “NewsWatch”. The piece airs today, between 7:00 and 7:30am. The press release goes to great lengths to underline the popularity of the channel and network and the fact that PMCB<\/a>‘s story has the potential to reach the 96 million U.S. households that are the estimated audience of NewsWatch.<\/p>\n

Traders obviously thought that this sort of early morning exposure was great for the company too and bought PMCB<\/a> all the way up to its close at $0.134 per share. The company’s previous few news announcements did nothing to stop the steady decline from April’s spike of over $0.20 per share.<\/p>\n

Sadly, PMCB<\/a> is still being pumped. In fact, it is easily among the most heavily promoted OTC stocks of 2015 so far. We have tracked close to 150 promotional emails advertising PMCB<\/a>‘s stock, the majority of them padded with monetary compensation. While the compensation handed out to pumpers is relatively modest, the effort to advertise PMCB<\/a> is obviously very focused.<\/p>\n

The company was pumped heavily back when it was trading as Nuvilex as well, with over 80 promotional emails sent for the old NVLX ticker.<\/p>\n

How much of a further impact today’s exposure will have on the share price remains to be seen. PMCB<\/a>‘s fiscal year end is in April so it will be another month until the company’s next report gets published.<\/p>\n","protected":false},"excerpt":{"rendered":"

On Friday Pharmacyte Biotech Inc (OTCMKTS:PMCB) was back to lows of just over $0.10 per share. A press release that the company dropped near the opening bell yesterday reversed its red streak and pushed...<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1635],"class_list":["post-6117","post","type-post","status-publish","format-standard","hentry","category-news","tag-pmcb"],"_links":{"self":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/posts\/6117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/comments?post=6117"}],"version-history":[{"count":0,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/posts\/6117\/revisions"}],"wp:attachment":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/media?parent=6117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/categories?post=6117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/tags?post=6117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}